Disease · MONDO_0006206
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: deaths from any cause | 225 of 322 | 244 of 321 | 643 | NCT05116189 | Trial comparisons |
| Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: serious adverse events | 178 of 320 | 122 of 318 | 638 | NCT05116189 | Trial comparisons |
| Carboplatin and Gemcitabine + Bevacizumab vs Carboplatin and Gemcitabine + Placebo: serious adverse events | 90 of 247 | 59 of 233 | 480 | NCT00434642 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: Number of Participants With Adverse Events | 73 of 73 | 75 of 75 | 148 | NCT01610206 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: deaths from any cause | 54 of 73 | 63 of 75 | 148 | NCT01610206 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: serious adverse events | 20 of 73 | 63 of 75 | 148 | NCT01610206 | Trial comparisons |
| Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetixumab + SL-172154: Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab | 20 of 21 | 65 of 65 | 86 | NCT05483933 | Trial comparisons |
| Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetuximab + SL-172154: deaths from any cause | 12 of 21 | 30 of 65 | 86 | NCT05483933 | Trial comparisons |
| Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetuximab + SL-172154: serious adverse events | 4 of 21 | 17 of 65 | 86 | NCT05483933 | Trial comparisons |
| Pegylated Liposomal Doxorubicin + SL-172154 vs Mirvetuximab + SL-172154: Immunogenicity to SL-172154 | 0 of 20 | 38 of 60 | 80 | NCT05483933 | Trial comparisons |
| Alisertib 50 mg (Platinum-Refractory) vs Alisertib 50 mg (Platinum-Resistant): serious adverse events | 4 of 6 | 7 of 25 | 31 | NCT00853307 | Trial comparisons |
| Nintedanib 150mg vs Nintedanib 200mg: serious adverse events | 3 of 7 | 4 of 12 | 19 | NCT01314105 | Trial comparisons |
| Nintedanib 150mg vs Nintedanib 200mg: Dose Limiting Toxicities During Treatment Course 1 | 1 of 6 | 1 of 6 | 12 | NCT01314105 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006206/comparisons